Online supplementary table 2. Study event table

Protocol activities	Screening period	Double-blind crossover part Visits/each treatment period			Open-label Follow-up extension				Post-treatment period
	Screening visit	Baseline Day 1 pre-dose	Day 5 ± 2	Day 14 ± 2	TC Week 2	Month 1	Month 3	Month 6	End-of-study visit
IC	x								
Demography and substance use	x								
Physical examination	x	x		x					x
Weight	x	x	x	x					x
Height and BMI	x								
Daytime oxygen saturation (SpO2)	x								
HR and BP	x	x	x	x		x	x	x	x
12-lead ECG	x	x[1]	x	x		x	x	x	x
Laboratory safety assessments									
Haematology	x	x		x		x	x	x	x
Chemistry	x	x[2]		x[2]		x[2]	x[2]	x[2]	x[2]
Urinalysis	x	x		x		x	x	x	x
Serology	x								
Testing ability to swallow capsules	x								
Pregnancy test for females of childbearing potential	x	x					x		x
24-hour Holter ECG	x			x					
Eligibility criteria and decision of entry	x								
Study treatment		x							
SVC	x[3]	x[4]	x[4]	x[4]		x[4]	x[4]	x[4]	

SNP		x	x	x		x	x	x	
Overnight oxygen saturation (SpO2)		x	x	x		x	x	x	
Maximal grip strength and submaximal grip strength endurance		x	x	x					
CGI-C			x	x					
VAS addressing fatigue		x	x	x					
EQ-5D-5L		x		x		x	x	x	
ALSFRS-R scoring		x		x		x	x	x	
SF-36		x		x		x	x	x	
Blood sampling for levosimendan PK		x[5]	x	x					
Blood sampling for riluzole concentration		x		x					
Blood sample for exploratory biomarkers		x				x		x	
Blood sample for PG		x[6]							
Non-invasive ventilator support, permanent continuous ventilator dependence, tracheostomy and survival status		x							
Medical history and current medical conditions	x								
AEs and SAEs	x								
Concomitant treatments	x								

TC = telephone contact; BMI = body mass index; CGI-C = Clinical Global Impression of Change; VAS = visual analogue scale; EQ-5D-5L = European Quality of Life Five Dimension Five Level Scale; SF-36 = Short-form health survey; PK = pharmacokinetics; PG = pharmacogenomics; SAE =

[1] 3 baseline recordings

[2] Except thyroid-stimulating hormone (TSH)

[3] Only in sitting position

[4] In sitting and supine position

[5] No pre-dose sample during the 1st treatment period

[6] One sample preferably during visit 1 of the 1st treatment period